Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsResearchers investigated the effects of reducing the dose of posttransplantation cyclophosphamide (PTCy) followed by α-galactosylceramide, a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect.
[Scientific Reports]
6445212 BWTF6XYK items 1 apa 0 default asc 1 163850 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-638eebec69aa40ed9747673574aea030%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22BWTF6XYK%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nakamura%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-23%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ENakamura%2C%20M.%2C%20Meguri%2C%20Y.%2C%20Ikegawa%2C%20S.%2C%20Kondo%2C%20T.%2C%20Sumii%2C%20Y.%2C%20Fukumi%2C%20T.%2C%20Iwamoto%2C%20M.%2C%20Sando%2C%20Y.%2C%20Sugiura%2C%20H.%2C%20Asada%2C%20N.%2C%20Ennishi%2C%20D.%2C%20Tomida%2C%20S.%2C%20Fukuda-Kawaguchi%2C%20E.%2C%20Ishii%2C%20Y.%2C%20Maeda%2C%20Y.%2C%20%26amp%3B%20Matsuoka%2C%20K.%20%282021%29.%20Reduced%20dose%20of%20PTCy%20followed%20by%20adjuvant%20%26%23x3B1%3B-galactosylceramide%20enhances%20GVL%20effect%20without%20sacrificing%20GVHD%20suppression.%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2C%20%3Ci%3E11%3C%5C%2Fi%3E%281%29%2C%2013125.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-92526-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-92526-z%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DBWTF6XYK%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reduced%20dose%20of%20PTCy%20followed%20by%20adjuvant%20%5Cu03b1-galactosylceramide%20enhances%20GVL%20effect%20without%20sacrificing%20GVHD%20suppression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Makoto%22%2C%22lastName%22%3A%22Nakamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yusuke%22%2C%22lastName%22%3A%22Meguri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuntaro%22%2C%22lastName%22%3A%22Ikegawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takumi%22%2C%22lastName%22%3A%22Kondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuichi%22%2C%22lastName%22%3A%22Sumii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takuya%22%2C%22lastName%22%3A%22Fukumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miki%22%2C%22lastName%22%3A%22Iwamoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasuhisa%22%2C%22lastName%22%3A%22Sando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroyuki%22%2C%22lastName%22%3A%22Sugiura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noboru%22%2C%22lastName%22%3A%22Asada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisuke%22%2C%22lastName%22%3A%22Ennishi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuta%22%2C%22lastName%22%3A%22Tomida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emi%22%2C%22lastName%22%3A%22Fukuda-Kawaguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yasuyuki%22%2C%22lastName%22%3A%22Ishii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshinobu%22%2C%22lastName%22%3A%22Maeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ken-ichi%22%2C%22lastName%22%3A%22Matsuoka%22%7D%5D%2C%22abstractNote%22%3A%22Posttransplantation%20cyclophosphamide%20%28PTCy%29%20has%20become%20a%20popular%20option%20for%20haploidentical%20hematopoietic%20stem%20cell%20transplantation%20%28HSCT%29.%20However%2C%20personalized%20methods%20to%20adjust%20immune%20intensity%20after%20PTCy%20for%20each%20patient%5Cu2019s%20condition%20have%20not%20been%20well%20studied.%20Here%2C%20we%20investigated%20the%20effects%20of%20reducing%20the%20dose%20of%20PTCy%20followed%20by%20%5Cu03b1-galactosylceramide%20%28%5Cu03b1-GC%29%2C%20a%20ligand%20of%20iNKT%20cells%2C%20on%20the%20reciprocal%20balance%20between%20graft-versus-host%20disease%20%28GVHD%29%20and%20the%20graft-versus-leukemia%20%28GVL%29%20effect.%20In%20a%20murine%20haploidentical%20HSCT%20model%2C%20insufficient%20GVHD%20prevention%20after%20reduced-dose%20PTCy%20was%20efficiently%20compensated%20for%20by%20multiple%20administrations%20of%20%5Cu03b1-GC.%20The%20ligand%20treatment%20maintained%20the%20enhanced%20GVL%20effect%20after%20reduced-dose%20PTCy.%20Phenotypic%20analyses%20revealed%20that%20donor-derived%20B%20cells%20presented%20the%20ligand%20and%20induced%20preferential%20skewing%20to%20the%20NKT2%20phenotype%20rather%20than%20the%20NKT1%20phenotype%2C%20which%20was%20followed%20by%20the%20early%20recovery%20of%20all%20T%20cell%20subsets%2C%20especially%20CD4%2BFoxp3%2B%20regulatory%20T%20cells.%20These%20studies%20indicate%20that%20%5Cu03b1-GC%20administration%20soon%20after%20reduced-dose%20PTCy%20restores%20GVHD-preventing%20activity%20and%20maintains%20the%20GVL%20effect%2C%20which%20is%20enhanced%20by%20reducing%20the%20dose%20of%20PTCy.%20Our%20results%20provide%20important%20information%20for%20the%20development%20of%20a%20novel%20strategy%20to%20optimize%20PTCy-based%20transplantation%2C%20particularly%20in%20patients%20with%20a%20potential%20relapse%20risk.%22%2C%22date%22%3A%222021-06-23%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-92526-z%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-021-92526-z%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-23T16%3A35%3A07Z%22%7D%7D%5D%7D
Nakamura, M., Meguri, Y., Ikegawa, S., Kondo, T., Sumii, Y., Fukumi, T., Iwamoto, M., Sando, Y., Sugiura, H., Asada, N., Ennishi, D., Tomida, S., Fukuda-Kawaguchi, E., Ishii, Y., Maeda, Y., & Matsuoka, K. (2021). Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Scientific Reports, 11(1), 13125. https://doi.org/10.1038/s41598-021-92526-z Cite
